All In Biotech

BLA 019991 · Novo Nordisk INC

Novolin 70/30

Insulin Recombinant Human, Insulin Susp Isophane Recombinant Human · Injection · Insulin

Last checked: Nov 20, 2026Latest source record: Nov 23, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1991

Jun 25, 1991

Approved uses

1

Original approval plus efficacy supplements

Registered trials

100

15 Phase 3, 0 recruiting

FAERS reports

5,946

3,872 serious, 612 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 6, 2023.

NOVOLIN 70/30 is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. Limitations of Use: In NOVOLIN 70/30, the proportions of short-acting and intermediate-acting insulins are fixed and do not allow for basal versus prandial dose adjustments. NOVOLIN 70/30 is a mixture of human insulin isophane, an intermediate-acting human insulin, and human insulin, a short-acting human insulin, indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. ( 1 )

Mechanism: The primary activity of insulin, including NOVOLIN 70/30, is the regulation of glucose metabolism. Insulins lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 25, 1991 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
  • NOVOLIN 70/30 · INSULIN RECOMBINANT HUMAN 30 UNITS/ML; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN 70 UNITS/ML · INJECTABLE, INJECTION · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Insulin Recombinant Human" as an intervention, any sponsor and status, largest first.

All 100 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • blood glucose increased902
  • nausea354
  • blood glucose decreased349
  • drug ineffective291
  • dyspnoea287
  • dizziness255
  • fatigue231
  • diarrhoea224
  • death222
  • asthenia208
  • renal failure202
  • weight decreased202

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004113
2005155
2006247
2007183
2008136
2009212
2010247
2011234
2012253
2013217
2014282
2015684
2016430
2017445
2018513
2019449
2020242
2021223
2022163
202398
2024197
2025155
202668

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Novolin 70-30 (Insulin NPh Hum/Reg Insulin Hm)

2024 spending

$26.9M

Beneficiaries

44,872

170,702 claims

Per beneficiary

$600

$4.45 per unit

View as table
YearSpending
2020$142,968,867
2021$132,943,279
2022$125,778,588
2023$112,846,649
2024$26,929,490

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1 on PubMed

Sponsor: Novo Nordisk

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.